Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres — the protective caps at the ends of chromosomes — allow immune cells to remain biologically “younger” for longer than normal, predisposing affected individuals to lymphoma and other cancers.

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML). They show that there are not just one, but four different subtypes of leukemia stem cells. This diversity could explain why one of the most important AML drugs does not work sufficiently in some patients or loses its effectiveness over time—resulting in the return of leukemia. This discovery lays an important foundation for more precise and long-term successful treatment strategies that could specifically overcome resistance mechanisms.

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseq^TM, a clinical whole-genome sequencing (WGS) test specifically for multiple myeloma. Approximately 35,000 new cases of multiple myeloma are diagnosed annually in the U.S., making it the second-most common blood cancer. The JAYseq test, developed and performed by TGen Clinical Laboratory, a CAP‑accredited lab founded by TGen, is intended for patients with newly diagnosed multiple myeloma, relapsed or refractory disease, or related plasma cell disorders.

A new study shows that cancer cells are better able to resist treatments when they have an abnormal number of chromosomes.